Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › risperidone

risperidone

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of risperidone

59 trials tracked of risperidone: 38 in phase 3 or 4 and 11 with published results. The most-cited published study has 140 citations.

59Trials tracked
38Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 23 Phase 3 15 Phase 2 13 Phase 1 2 Other / NA 6
  1. Phase 4 Treatment of Severe Childhood Aggression (The TOSCA Study) Completed · 140 cited
  2. Phase 4 Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis Completed · 111 cited
  3. Phase 4 Metabolic Effects of Antipsychotics in Children Completed · 77 cited
  4. Phase 4 Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy Completed · 72 cited
  5. Phase 4 Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART) Completed · 54 cited
  6. Phase 4 A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic Completed · 17 cited
Show 44 more trials
  1. Phase 3 Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia Completed · 12 cited
  2. Phase 3 Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients Completed · 11 cited
  3. Phase 3 A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment Completed · 7 cited
  4. Phase 4 Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode Completed · 6 cited
  5. Phase 4 Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone Completed · 2 cited
  6. Phase 4 Clozapine for Cannabis Use in Schizophrenia Completed
  7. Phase 4 Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia Completed
  8. Phase 4 Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder Completed
  9. Phase 4 Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS) Completed
  10. Phase 4 Different Safety Profile of Risperidone and Paliperidone Extended-release Completed
  11. Phase 4 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated Completed
  12. Phase 4 A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children Completed
  13. Phase 4 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed
  14. Phase 4 Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients Completed
  15. Phase 4 An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders Completed
  16. Phase 4 A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder Completed
  17. Phase 4 Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder Completed
  18. Phase 4 Antipsychotic Discontinuation in Alzheimer's Disease Completed
  19. Phase 4 Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia Completed
  20. Phase 4 Switching Medication to Treat Schizophrenia Completed
  21. Phase 3 Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia Completed
  22. Phase 3 Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone Completed
  23. Phase 3 A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia Completed
  24. Phase 3 Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia Completed
  25. Phase 3 Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia Completed
  26. Phase 3 Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar Completed
  27. Phase 3 Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents Completed
  28. Phase 3 Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use Completed
  29. Phase 3 Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone Completed
  30. Phase 3 Quetiapine Extended Release Depression Symptoms Completed
  31. Phase 3 A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia Completed
  32. Phase 3 Pharmacogenomics in Autism Treatment Completed
  33. Phase 2 A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder Completed
  34. Phase 2 Risperidone Treatment for Military Service Related Chronic Post Traumatic Stress Disorder Completed
  35. Phase 2 Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia Completed
  36. Phase 2 An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia Completed
  37. Phase 2 Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence Completed
  38. Phase 2 An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005) Completed
  39. Phase 2 Study of a Novel Antipsychotic ITI-007 in Schizophrenia Completed
  40. Phase 2 Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008) Completed
  41. Phase 2 Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy Completed
  42. Phase 2 A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication Completed
  43. Phase 2 A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients Completed
  44. Phase 2 Risperidone for the Treatment of Huntington's Disease Involuntary Movements Completed

Showing the 50 most-cited and recently-updated of 59 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Network meta-analysis compares risperidone and aripiprazole for autism irritability
Drug Pipeline Meta-analysis
Network meta-analysis compares risperidone and aripiprazole for autism irritability Risperidone and Aripiprazole Help Autistic Behaviors But Carry Risks
This network meta-analysis of randomized trials synthesized evidence on antipsychotics for autism spectrum disorder. Combined risperidone an…
Two antipsychotic drugs help reduce irritability in autistic people, but they also raise the risk of side effects compared to placebo.
medRxiv May 14, 2026
FDA Approves Perseris (risperidone) for Treatment of Schizophrenia in Adults
Psychiatry FDA Approval
FDA Approves Perseris (risperidone) for Treatment of Schizophrenia in Adults FDA approves new monthly shot Perseris for schizophrenia in adults.
The FDA approved Perseris, a long-acting injectable atypical antipsychotic, for the treatment of schizophrenia in adults. It is administered…
The FDA approved Perseris, a once-monthly injectable form of risperidone, for treating schizophrenia in adults. This new option may help pat…
FDA May 6, 2026
Systematic review finds weak link between atypical antipsychotics and MASLD in youth
Gastroenterology Meta-analysis
Systematic review finds weak link between atypical antipsychotics and MASLD in youth Atypical antipsychotics show a small link to liver disease in young patients
This systematic review and meta-analysis of 3 studies examined the association between atypical antipsychotics and metabolic dysfunction-ass…
A review of three studies found a small link between atypical antipsychotics and liver disease in children, but the evidence is limited.
May 1, 2026
Case report review suggests LAI paliperidone stabilizes behavior in a 9-year-old with TBI over two years
Psychiatry Sys. Review
Case report review suggests LAI paliperidone stabilizes behavior in a 9-year-old with TBI over two years Long-acting shots help a boy control severe brain injury rage
This case report review describes a 9-year-old boy with severe traumatic brain injury and posttraumatic confusional state treated with long-…
A boy with severe brain injury rage found calm after months of failed pills, showing long-acting shots could help when daily medicine fails
Frontiers Apr 29, 2026